News

CanPharma News Feed

No more posts
CBD-OMS-1200x800.png
28/Aug/2019

Research shows that CBD can be used to decrease the frequency of seizures without the psychoactive properties of medical cannabis.

The World Health Organisation (WHO) announced that there medicinal and therapeutic benefits of cannabidiol (CBD) and one of the pathologies which can be treated is epilepsy.

Epilepsy is when two or more unprovoked and unexpected seizures arise. Seizures are brief episodes of involuntary movement that may involve the entire body (generalized) or a part of the body (partial).

Medically, refractory epilepsy remains an area of scientific interest as up to 35% of patients continue to suffer from seizures despite current therapies. Recent evidence has focused on the benefit of cannabidiol (CBD), a marijuana plant-based product with no psychoactive properties, can be used to decrease seizure frequency.

Medical Research with Oral CBD

In 2019, a group of researchers analysed several published articles of this pure oral CBD extract as an additional therapy for treating refractory epilepsy, Lennox-Gastaut and Dravet syndromes, convulsive seizures decrease by 50%. Additionally, in patients with treatment-resistant epilepsy of multiple aetiologies, similar benefits were observed.

Furthermore, a stopped/decreased dose of anti-seizure medication was observed when taking the CBD oil.

The therapeutic potential of CBD in epilepsy exists, however, further studies are still needed to better understand the full mechanism of action.

Source:

https://www.kalapa-clinic.com/en/new-stance-cbd-who/

 


chronic-pain-medical-cannabis-investigation.jpg
21/Aug/2019

Chronic pain (CP) is a long-lasting unpleasant sensorial and emotional experience without the acute warning signals of physiological nociception that persists past normal healing time and usually lasts or recurs for more than 3 months. It is a common and economically important health issue, affecting approximately 20% of people worldwide and accounting accordingly for 15-20% of medical consultations.

According to an exploratory analysis of anonymized 12-week open-label data provided by the German Pain e-Registry add-on treatment with the cannabis spray Sativex was effective and well-tolerated. Data were analyzed by scientists of the Institute of Neurological Sciences in Nuremberg, Germany, and other German institutions.
Among that 30.228 cases documented in the database in 2017, 800 (2.6%) received a treatment with Sativex containing THC and CBD in a ratio of about 1:1. Authors found a significant treatment effect.

Beneficial effects using CBD:THC oromucosal spray

Authors concluded that the Beneficial effects found for CP patients in this analysis clearly out weighted the potential risks of treatments and confirmed that THC:CBD oromucosal spray provides an effective add-on measure for patients suffering either from elsewhere refractory neuropathic pain conditions as well as those presenting with a pain phenotype suggestive for underlying neuropathic mechanisms.

Source:

Journal of Pain Research : Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain


Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.

MEMBER OF

footerlogos

OFFICES

CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg
Germany

CanPharma Portugal
Rua João Fernandes
Lavrador 1 – Sala 6 2825-
132 Vila Nova de Caparica
Portugal

REPRESENTATIVE OFFICES

Berlin
Neue Kantstraße 18
14057 Berlin
Germany

Barcelona
Gran de Gràcia 15, 1-1
08012 Barcelona
Spain